170 related articles for article (PubMed ID: 36752338)
1. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
4. Computational analyses of curcuminoid analogs against kinase domain of HER2.
Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
6. Computational prediction of 11β-hydroxysteroid dehydrogenase inhibitors from n-butanol fraction of
Aribigbola TC; Omoboyowa DA; Bodun DS
J Biomol Struct Dyn; 2023 Sep; ():1-14. PubMed ID: 37698347
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
8. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
Matore BW; Roy PP; Singh J
J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
[TBL] [Abstract][Full Text] [Related]
10. Potential inhibitors for FKBP51: an
Barge S; Jade D; Ayyamperumal S; Manna P; Borah J; Nanjan CMJ; Nanjan MJ; Talukdar NC
J Biomol Struct Dyn; 2022; 40(24):13799-13811. PubMed ID: 34709133
[TBL] [Abstract][Full Text] [Related]
11. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
12. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
13.
Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
[TBL] [Abstract][Full Text] [Related]
14. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, molecular docking and molecular dynamics simulation for screening and identifying anti-dengue phytocompounds.
Vora J; Patel S; Athar M; Sinha S; Chhabria MT; Jha PC; Shrivastava N
J Biomol Struct Dyn; 2020 Apr; 38(6):1726-1740. PubMed ID: 31057055
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel PARP-1 inhibitors using tandem
Bhatnagar A; Nath V; Kumar N; Kumar V
J Biomol Struct Dyn; 2024 Apr; 42(7):3396-3409. PubMed ID: 37216358
[TBL] [Abstract][Full Text] [Related]
18. Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
Rajagopal K; Sri VB; Byran G; Gomathi S
Curr Drug Res Rev; 2022; 14(1):61-72. PubMed ID: 34139975
[TBL] [Abstract][Full Text] [Related]
19. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]